Therefore, some catalytically defective RPTKs involved in tumorigenesis, such as PTK7, Erb-B2 receptor tyrosine kinase 3 (ErbB3), and EPH receptor A10 (EphA10), are considered target molecules for cancer therapy [3,4,5,6,7]. The gene discussed is PTK7; the disease is cancer.